Shares of Merck and Co. (NYSE: MRK) this week pared some of their recent gains even as the ex-dividend date approaches. While
Merck & Company Inc.
-(MRK)
XNYS:MRK
Merck’s (MRK) Q3 results beat estimates; sales boosted by oncology and vaccines
Merck (NYSE: MRK) surpassed analysts’ expectations for revenue and earnings in the third quarter of 2019, sending the shares climbing 2.5% in
Merck rises on oncology strength post Q2 earnings
Shares of pharmaceutical giant Merck (NYSE: MRK) rose 3% before the market hours on Tuesday after the company reported second-quarter results that
Pharma stocks: Merck is on a buying spree
Several merger and acquisition deals are being announced in the healthcare sector, the most recent one being the acquisition of Array Biopharma
What’s in store for top pharma stocks this year
The stocks of leading pharmaceutical firms shifted to growth mode this year after winding up 2018 on a low note, in line
KEYTRUDA helps Merck to report Q1 earnings beat, raises 2019 outlook
Shares of the pharma giant Merck (MRK) rose 2% before the market hours after the company surpassed estimates on the headline numbers.
Calendar: Earnings of Alphabet, Pfizer, Merck, Apple, Gilead on queue
Alphabet, Pfizer, Merck, Apple, Gilead Sciences, and more earnings are scheduled for the week between April 29 and May 3. Check out
Axsome Therapeutics stock climbs to 34-month high
After the slump on weak quarterly results, investors turned positive on Axsome Therapeutics (AXSM) stock, which climbed to the 34-month high of
Immune Design stock more than triples as it gets acquired by Merck
Merck (MRK) announced today that it will acquire immunotherapy developer Immune Design (IMDZ) for $5.85 per share in cash for an approximate value
Earnings: Array BioPharma delivers strong Q2 results, investors cheer
Array BioPharma (ARRY) reported 44% jump in second-quarter revenue to $82.5 million, driven by higher product sales and recognition of $40 million
Alexion Pharma stock jumps after Q4 results top expectations
Benefitting from the continued sales growth across all markets, led by cancer drug Soliris, Alexion Pharma (ALXN) Monday reported a double-digit increase
Merck’s stock gains after Q4 results beat estimates
Merck’s (MRK) shares climbed over 3% in morning trade on Friday after the company topped revenue and earnings expectations for the fourth
Earnings preview: Merck to ride the wave of expanding oncology portfolio in Q4
The general market sentiment on Merck & Co. (MRK) is quite bullish ahead of the drug maker’s fourth-quarter earnings report. Analysts predict
Merck strengthens animal health division with $2.4-bln Antelliq buyout
Taking a cue from the growing demand for animal care products, healthcare service providers and pharma companies are enhancing their offerings in
Merck announces management changes
Merck (MRK) announced that Adam Schechter, President of Global Human Health (GHH) division will step down from his present role at the
Moderna raises over $600-million through IPO, falls below IPO price
Biotech company Moderna raised above $600 million on Thursday by selling about 26 million of its common stock at $23 a share,
Bayer looks at global lay-offs and divestments post Monsanto acquisition
German drugmaker Bayer (Frankfurt:BAYGn) on Thursday announced the divestment of many businesses, about 12,000 layoffs and $3.8 billion in impairments. The Frankfurt-listed
Tesaro shares spike on buyout news, trading halted
Shares of Tesaro (TSRO), an oncology-focused biopharma company, skyrocketed after the news that it has been working with advisors for a possible sale.
Dealing with semiconductor stocks in times of slowdown
With the semiconductor industry showing signs of cooling off - thanks to the demand crunch and tariff crisis - the market sentiment